Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Jan. 31, 2015 | Mar. 16, 2015 | |
Document and Entity Information: | ||
Entity Registrant Name | Arax Holdings Corp | |
Document Type | 10-Q | |
Document Period End Date | 31-Jan-15 | |
Amendment Flag | FALSE | |
Entity Central Index Key | 1566243 | |
Current Fiscal Year End Date | -21 | |
Entity Common Stock, Shares Outstanding | 10,300,000 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Document Fiscal Year Focus | 2015 | |
Document Fiscal Period Focus | Q1 |
CONDENSED_BALANCE_SHEETS
CONDENSED BALANCE SHEETS (USD $) | Jan. 31, 2015 | Oct. 31, 2014 |
Current Assets | ||
Cash and Cash Equivalents | $0 | $0 |
Prepaid Expenses | 2,000 | 0 |
Total Current Assets | 2,000 | 0 |
Total Assets | 2,000 | 0 |
Current Liabilities | ||
Loan from related party | 55,015 | 45,458 |
Total Current Liabilities | 55,015 | 45,458 |
Total Liabilities | 55,015 | 45,458 |
Stockholders' Deficit: | ||
Common stock, par value $0.001; 75,000,000 shares authorized; 10,300,000 shares issued and outstanding | 10,300 | 10,300 |
Additional paid in capital | 25,548 | 25,548 |
Accumulated deficit | -88,863 | -81,306 |
Total Stockholders' Deficit | -53,015 | -45,458 |
Total Liabilities and Stockholders' Deficit | $2,000 | $0 |
CONDENSED_BALANCE_SHEETS_Paren
CONDENSED BALANCE SHEETS (Parenthetical) (USD $) | Jan. 31, 2015 | Oct. 31, 2014 |
Assets [Abstract] | ||
Common Stock, par value | $0.00 | $0.00 |
Common Stock, shares authorized | 75,000,000 | 75,000,000 |
Common Stock, shares issued | 10,300,000 | 10,300,000 |
Common Stock, shares Outstanding | 10,300,000 | 10,300,000 |
CONDENSED_STATEMENTS_OF_OPERAT
CONDENSED STATEMENTS OF OPERATIONS (USD $) | 3 Months Ended | |
Jan. 31, 2015 | Jan. 31, 2014 | |
Income Statement [Abstract] | ||
REVENUES | $0 | $0 |
OPERATING EXPENSES | ||
Depreciation Expense | 0 | 29 |
Bank Service Charges | 0 | 24 |
Professional Fees | 7,557 | 4,354 |
Loss on Disposal of Fixed Assets | 0 | 428 |
TOTAL OPERATING EXPENSES | 7,557 | 4,836 |
NET LOSS FROM OPERATIONS | -7,557 | -4,836 |
PROVISION FOR INCOME TAXES | 0 | 0 |
NET LOSS | ($7,557) | ($4,836) |
NET LOSS PER SHARE: BASIC AND DILUTED | $0 | $0 |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED | 10,300,000 | 10,300,000 |
CONDENSED_STATEMENT_OF_CHANGES
CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (USD $) | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Deficit |
Beginning Balance, Amount at Oct. 31, 2014 | 10,300 | 25,548 | -81,306 | -45,458 |
Beginning Balance, Shares at Oct. 31, 2014 | 10,300,000 | |||
Net loss for the period | $0 | $0 | ($7,557) | ($7,557) |
Beginning Balance, Amount at Jan. 31, 2015 | 10,300 | 25,548 | -88,863 | -53,015 |
Beginning Balance, Shares at Jan. 31, 2015 | 10,300,000 |
CONDENSED_STATEMENTS_OF_CASH_F
CONDENSED STATEMENTS OF CASH FLOWS (USD $) | 3 Months Ended | |
Jan. 31, 2015 | Jan. 31, 2014 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net loss for the period | ($7,557) | ($4,836) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation expense | 0 | 29 |
Loss on disposal of fixed assets | 0 | 428 |
Changes in operating assets and liabilities: | ||
Prepaid expenses | -2,000 | 0 |
CASH USED IN OPERATING ACTIVITIES | -9,557 | -4,379 |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
CASH USED IN INVESTING ACTIVITIES | 0 | 0 |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Loan from related party | 9,557 | 627 |
CASH PROVIDED BY FINANCING ACTIVITIES | 9,557 | 627 |
Net increase (decrease) in cash and cash equivalents | 0 | -3,752 |
Cash, beginning of period | 0 | 3,752 |
Cash, end of period | 0 | 0 |
SUPPLEMENTAL DISCLOSURES OF CASHFLOW INFORMATION | ||
Interest paid | 0 | 0 |
Income tax paid | 0 | 0 |
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES | ||
Disposal of equipment without cash proceeds | 0 | 428 |
Forgiveness of loan from related party | 0 | 4,848 |
Total Non-cash Investing and Financing Activities | $0 | $5,276 |
1_ORGANIZATION_AND_NATURE_OF_B
1. ORGANIZATION AND NATURE OF BUSINESS | 3 Months Ended |
Jan. 31, 2015 | |
ORGANIZATION AND NATURE OF BUSINESS | |
ORGANIZATION AND NATURE OF BUSINESS | Arax Holdings Corp. (“the Company”) was incorporated under the laws of the State of Nevada on February 23, 2012 with a business plan to sell hot dogs from mobile hot dog stands throughout the major cities in Mexico |
Effective January 16, 2014, Vladimir Leonov, the Chief Executive Officer, majority shareholder and sole director of the Company sold 8,000,000 shares of common stock of the Company (approximately 77% of the issued and outstanding shares of common stock of the Company) owned by him to Thru Pharma, LLC (d/b/a pharmaCline), a Delaware limited liability company (“Thru Pharma”), for total cash consideration of $275,000 in a private transaction (the “Acquisition”). The Acquisition resulted in a change in control of the Company. Simultaneous with the closing of the Acquisition, Mr. Leonov resigned as a director and from all offices he held with the Company, and Steven J. Keough, was elected as a director of the Company and appointed as the Company’s Chief Executive Officer, President, Secretary and Treasurer. | |
Following the changes in control and management of the Company related to the Acquisition, we have been reevaluating our business plan. We have been assessing potential new business models to replace our previous business model relating to hot dog stands in Mexico. While it is quite possible there will be a new business model for us, we have not finalized the decision. We have been reviewing business sectors other than the food sector the Company is currently engaged in and it is possible that a new business model could relate to a new business sector other than the food sector. It is also possible any new business model could entail a capital restructuring of the Company in order to provide new capital and a broader base of shareholders. Such a capital restructuring of the Company could involve a merger or acquisition of assets through various techniques, including a possible reverse-merger. At January 31, 2015, and as of the date of this filing, we continue to assess these opportunities and structures as well as the various pre-requisite actions needed to finalize and implement any new business model. | |
Pursuant to a Consulting Agreement dated as of October 8, 2013, by and between Thru Pharma and Strategic Universal Advisors, LLC (“Strategic”), as amended effective January 17, 2014 and February 9, 2015 (the “Consulting Agreement”), Thru Pharma transferred (effective April, 2014) 7,660,000 shares of the Company’s common stock to Strategic (“the Transfer”) as partial compensation for consulting services provided to Thru Pharma by Strategic. | |
In connection with the Transfer, Strategic granted to Mr. Keough, a control person of the Company and Thru Pharma, an irrevocable proxy (“the Irrevocable Proxy”), to vote all of said 7,660,000 shares of common stock until the later of (i) the achievement of the objectives by Thru Pharma and Strategic set out in the consulting Agreement and (ii) June 30, 2015. | |
As part of the Consulting Agreement, Thru Pharma also agreed that upon the closing of a merger or acquisition (an “M&A Transaction”) of a public entity, resulting in Thru Pharma being the controlling owner of the entity that was the subject of the M&A Transaction, Thru Pharma would cause such entity to issue to Strategic a non-qualified stock option or warrant to purchase 1,000,000 (one million) shares of common stock of the entity that was the subject of the M&A Transaction. Such option or warrant will be of five-year duration, exercisable at the greater of the fair market value per share on the date of the grant or $0.10 per share, as well as other routine terms. | |
Notwithstanding anything to the contrary provided in the Consulting Agreement or elsewhere, in no event would Thru Pharma be directly and/or indirectly obligated to enter into or complete any particular M&A Transaction, including, but not limited to, any M&A Transaction with the Company. | |
The Company’s status as a “shell company” as of the date of this report remains unchanged. |
2_GOING_CONCERN
2. GOING CONCERN | 3 Months Ended |
Jan. 31, 2015 | |
GOING CONCERN | |
GOING CONCERN | The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has not generated any revenues as of January 31, 2015. The Company has incurred losses since Inception (February 23, 2012) resulting in an accumulated deficit of $88,863 as of January 31, 2015 and stockholders’ deficit of $53,015. The Company currently has a working capital deficit, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. |
Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it can be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern. |
3_SUMMARY_OF_SIGNIFICANT_ACCOU
3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Jan. 31, 2015 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Basis of Presentation |
The Company has adopted an October 31 fiscal year end. | |
The accompanying unaudited financial statements have been prepared in accordance with the instructions from Regulation S-X and do not include all of the information and disclosures required by generally accepted accounting principles for complete financial statements. All adjustments that are, in the opinion of management, necessary for a fair presentation of the results of operations for the interim period, and to make the financial statements not misleading, have been made and are of a recurring nature unless otherwise disclosed herein. The results of operations for such interim period are not necessarily indicative of operations for a full year. | |
Development Stage Company | |
The Company is in the development stage as defined under the then current Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915-205 “Development-Stage Entities” and among the additional disclosures required as a development stage company that its financial statements were identified as those of a development stage company, and that the statements of operations, stockholders’ deficit and cash flows disclosed activity since the date of its Inception (February 23, 2012) as a development stage company. Effective June 10, 2014 FASB changed its regulations with respect to Development Stage Entities and these additional disclosures are no longer required for annual reporting periods beginning after December 15, 2014 with the option for entities to early adopt these new provisions. The Company has elected to early adopt these provisions and consequently these additional disclosures are not included in these financial statements. | |
Use of Estimates | |
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |
Cash and Cash Equivalents | |
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. | |
Fair Value of Financial Instruments | |
The Company’s financial instruments consist of amounts due to its related parties. The carrying amount of these financial instruments approximates fair value due to length of maturity. | |
Income Taxes | |
Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. | |
The Company accounts for income taxes under the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, “Accounting for Income Taxes”. It prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As a result, the Company has applied a more-likely-than-not recognition threshold for all tax uncertainties. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. The Company is subject to taxation in the United States. All of the Company’s tax years are subject to examination by Federal and state jurisdictions. | |
The Company classifies penalties and interest related to income taxes as income tax expense in the Statements of Operations. | |
Revenue Recognition | |
The Company will recognize revenue in accordance with Accounting Standards Codification No. 605, "Revenue Recognition" ("ASC-605"), ASC-605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required. | |
Advertising | |
The Company follows the policy of charging the costs of advertising to expenses incurred. The Company incurred $0 in advertising costs during the three months ended January 31, 2015 and 2014. | |
Basic Income (Loss) Per Share | |
Basic income (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net loss available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity instruments. There were no such potentially dilutive debt or equity instruments issued or outstanding during the three month periods ending January 31, 2015 and 2014. | |
Recent Accounting Pronouncements | |
The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements, and does not believe any of these pronouncements will have a material impact on the company. |
4_STOCKHOLDERS_DEFICIT
4. STOCKHOLDERS' DEFICIT | 3 Months Ended |
Jan. 31, 2015 | |
COMMON STOCK | |
STOCKHOLDERS' DEFICIT | Common Stock |
The Company is authorized to issue 75,000,000 shares of common stock with a par value of $0.001 per share. | |
No shares of common stock were issued during the three month periods ended January 31, 2015 or 2014. | |
The Company had 10,300,000 shares of common stock issued and outstanding as of January 31, 2015. | |
Additional Paid in Capital | |
The Company owed its principal shareholder and Chief Executive Officer Vladimir Leonov, a total of $4,221 as of October 31, 2013, in the form of an unsecured loan. The note was due on demand and was non-interest bearing. | |
During the three months ended January 31, 2014, Mr. Leonov advanced the Company a further $627 for working capital purposes. | |
Effective January 16, 2014, coincidental with the sale of his controlling interest in the Company, Mr. Leonov forgave repayment of his outstanding loan balance which was credited to additional paid in capital at that time. |
5_RELATED_PARTY_TRANSACTIONS
5. RELATED PARTY TRANSACTIONS | 3 Months Ended |
Jan. 31, 2015 | |
RELATED PARTY TRANSACTION | |
RELATED PARTY TRANSACTIONS | In support of the Company’s efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances are considered temporary in nature and have not been formalized by a promissory note. |
The Company owed its former principal shareholder and Chief Executive Officer Vladimir Leonov, a total of $4,221 as of October 31, 2013, in the form of an unsecured loan. The note was due on demand and was non-interest bearing. | |
During the three months ended January 31, 2014, Mr. Leonov advanced the Company a further $627 for working capital purposes. | |
Effective January 16, 2014, coincidental with the sale of his controlling interest in the Company, Mr. Leonov forgave repayment of his outstanding loan balance which was credited to additional paid in capital at that time. | |
The Company owed its principal shareholder, Thru Pharma, a total of $55,015 as of January 31, 2015, in the form of an intercompany payable. It is due on demand and is non-interest bearing. |
6_INCOME_TAXES
6. INCOME TAXES | 3 Months Ended |
Jan. 31, 2015 | |
INCOME TAXES | |
INCOME TAXES | Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. |
As of January 31, 2015, the Company had a net operating loss carry-forward of approximately $88,863 that may be used to offset future taxable income and begins to expire in 2031. Because of the change in ownership that occurred on January 16, 2014, net operating loss carry forwards could be limited as to use in future years. |
7_COMMITMENTS_AND_CONTINGENCIE
7. COMMITMENTS AND CONTINGENCIES | 3 Months Ended |
Jan. 31, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | On June 4, 2014, the Company was named as a defendant in a lawsuit filed by AMERIFINANCIAL, INC. (“AMERIFINANCIAL”), of Houston, Texas. The action relates primarily to a contract dispute between AMERIFINANCIAL and the Company’s former majority shareholder, THRU PHARMA, LLC. The dispute alleged an unpaid balance of $171,870 and five membership units in THRU PHARMA, LLC. The dispute does not allege any actions or inactions by the Company’s officers or representatives acting on behalf of the Company. Counsel for THRU PHARMA, LLC, has requested the Company be dismissed from the lawsuit, as it is not a party to the disputed contract. As the Company has been advised by its legal counsel there is no legal basis for the Company being a part of the lawsuit, the Company has not recognized a liability in connection with it. On November 18, 2014, counsel for THRU PHARMA, LLC, filed an Original Answer and Request for Rule 194 Disclosures with the court. The filing included a general denial of all allegations against all defendants. |
8_SUBSEQUENT_EVENTS
8. SUBSEQUENT EVENTS | 3 Months Ended |
Jan. 31, 2015 | |
SUBSEQUENT EVENTS | |
SUBSEQUENT EVENTS | In accordance with ASC 855-10, “Subsequent Events”, the Company has analyzed its operations subsequent to January 31, 2015 to the date these financial statements were issued on March 23, 2015, and has determined that it does not have any material subsequent events to disclose in these financial statements. |
3_SIGNIFICANT_ACCOUNTING_POLIC
3. SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
Jan. 31, 2015 | |
SIGNIFICANT ACCOUNTING POLICIES | |
Basis of Presentation | The Company has adopted an October 31 fiscal year end. |
The accompanying unaudited financial statements have been prepared in accordance with the instructions from Regulation S-X and do not include all of the information and disclosures required by generally accepted accounting principles for complete financial statements. All adjustments that are, in the opinion of management, necessary for a fair presentation of the results of operations for the interim period, and to make the financial statements not misleading, have been made and are of a recurring nature unless otherwise disclosed herein. The results of operations for such interim period are not necessarily indicative of operations for a full year. | |
Development Stage Company | The Company is in the development stage as defined under the then current Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915-205 “Development-Stage Entities” and among the additional disclosures required as a development stage company that its financial statements were identified as those of a development stage company, and that the statements of operations, stockholders’ deficit and cash flows disclosed activity since the date of its Inception (February 23, 2012) as a development stage company. Effective June 10, 2014 FASB changed its regulations with respect to Development Stage Entities and these additional disclosures are no longer required for annual reporting periods beginning after December 15, 2014 with the option for entities to early adopt these new provisions. The Company has elected to early adopt these provisions and consequently these additional disclosures are not included in these financial statements. |
Use of Estimates | The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents | The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. |
Fair Value of Financial Instruments | The Company’s financial instruments consist of amounts due to its related parties. The carrying amount of these financial instruments approximates fair value due to length of maturity. |
Income Taxes | Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. |
The Company accounts for income taxes under the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, “Accounting for Income Taxes”. It prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As a result, the Company has applied a more-likely-than-not recognition threshold for all tax uncertainties. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. The Company is subject to taxation in the United States. All of the Company’s tax years are subject to examination by Federal and state jurisdictions. | |
The Company classifies penalties and interest related to income taxes as income tax expense in the Statements of Operations. | |
Revenue Recognition | The Company will recognize revenue in accordance with Accounting Standards Codification No. 605, "Revenue Recognition" ("ASC-605"), ASC-605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required. |
Advertising | The Company follows the policy of charging the costs of advertising to expenses incurred. The Company incurred $0 in advertising costs during the three months ended January 31, 2015 and 2014. |
Basic Income (Loss) Per Share | Basic income (loss) per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net loss available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity instruments. There were no such potentially dilutive debt or equity instruments issued or outstanding during the three month period ending January 31, 2015 and 2014. |
Recent Accounting Pronouncements | The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements, and does not believe any of these pronouncements will have a material impact on the company. |
4_STOCKHOLDERS_DEFICIT_Details
4. STOCKHOLDERS' DEFICIT (Details Narrative) (USD $) | 3 Months Ended |
Jan. 31, 2015 | |
COMMON STOCK TRANSACTIONS: | |
Authorized to issue shares of common stock | 75,000,000 |
Shares of common stock with a par value per share | $0.00 |
Issued shares of common stock | 10,300,000 |
Shares issued in period | 8,000,000 |
Shares of common stock issued and outstanding | 10,300,000 |
5_RELATED_PARTY_TRANSACTIONS_D
5. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $) | 3 Months Ended | ||
Jan. 31, 2015 | Jan. 31, 2014 | Oct. 31, 2013 | |
Proceeds from related party debt | $9,557 | $627 | |
Vladimir Leonov | |||
Owed to related party | 0 | 4,221 | |
Proceeds from related party debt | 615 | ||
Thru Pharma | |||
Owed to related party | $55,015 |
6_INCOME_TAXES_Details_Narrati
6. INCOME TAXES (Details Narrative) (USD $) | Jan. 31, 2015 |
INCOME TAX AS FOLLOWS | |
Net operating loss carry-forward | $88,863 |